Andrew Herden has core competencies in Strategic Planning, Financial Optimization Strategies & Analysis, Portfolio & Capital Requirements and Corporate Performance Management. He is a Senior Award-Winning Global Finance Leader with proven expertise in leading teams and optimizing financial strategies, consistently driving high-percentage profit increases through multinational company leadership. He has created and spearheaded financial, planning and technology efforts in multinational corporations resulting in millions of dollars in savings, sales, revenue growth, and ROI.
Andrew served as a key member of a Global Business Development Team to support Finance and Tax Due Diligence for closing global deals valued at an aggregate of $660M and led valuation, financial due diligence, and financial integration to buyout Sentinel assets from Novartis Animal Health during their acquisition by Elanco, resulting in $410M deal and 80% in GP, as the largest animal health acquisition of its time.
Andrew’s roots are in Arkansas, but his studies and career have landed him in Austria, Germany, New Zealand and Australia. He is currently CFO with a Dallas, Texas firm.
Location: Arkansas and Texas